Obesity
China Approves Lilly and Innovent’s Mazdutide, Marking New Era for GLP-1 Obesity Drugs
Mazdutide; China approval; Innovent Biologics; Eli Lilly; GLP-1 obesity drugs; dual GCG/GLP-1 agonist; NMPA; weight management
BrightGene’s Dual GLP-1/GIP Agonist BGM0504 Shows Promise in Phase 2 Diabetes and Obesity Trials at ADA25
BrightGene; BGM0504; GLP-1/GIP agonist; ADA25; Type 2 diabetes; Obesity; Phase 2 clinical trial; weight management; HbA1c reduction; semaglutide; tirzepatide
Amgen Adjusts Phase 3 Dosing for MariTide After Midstage Side Effects Concerns
Amgen; MariTide; Phase 3; obesity treatment; dose escalation; vomiting; adverse events; clinical trial; GLP-1 receptor; GIP receptor
BrightGene’s BGM0504 Outperforms Novo Nordisk’s Semaglutide in Diabetes Trial, Eyes Showdown with Zepbound
BrightGene; diabetes; GLP-1/GIP receptor agonist; BGM0504; semaglutide; Novo Nordisk; Eli Lilly; Zepbound; clinical trial; HbA1c reduction; obesity; weight management
Diabetes and Obesity Drug Boom to Propel Lilly and Novo Nordisk to Pharma Sales Leadership by 2030: Evaluate
diabetes; obesity; pharmaceutical sales; Eli Lilly; Novo Nordisk; Evaluate report; top-selling drugs; tirzepatide; semaglutide; Mounjaro; Zepbound; Ozempic; Wegovy; CagriSema; 2030 forecast
Zealand Pharma’s Dual GLP-1/GLP-2 Agonist Dapiglutide Shows Promising 11.6% Weight Loss at 28 Weeks
Zealand Pharma; dapiglutide; GLP-1; GLP-2; weight loss; obesity; phase 1b trial; clinical trial; dual agonist; safety
Scholar Rock’s SMA drug helps Zepbound patients retain muscle in phase 2 trial
Scholar Rock; apitegromab; SMA drug; Zepbound; tirzepatide; muscle preservation; obesity; weight loss; phase 2 trial; lean mass; myostatin inhibitor
Lilly Makes All Zepbound Doses Available via Direct Pay Program
Zepbound; Eli Lilly; direct pay; LillyDirect; tirzepatide; obesity medication; dose availability; pharmacy platform
Lilly Posts Encouraging Early-Stage Weight Loss Data on Amylin Candidate
Eli Lilly; eloralintide; amylin candidate; weight loss; early-stage trial; obesity drug; clinical data; side effects
Novo Nordisk Plans Phase 3 Trials for Next-Generation Obesity Drug Amycretin
Novo Nordisk; amycretin; obesity; clinical trials; Phase 3; GLP-1; amylin receptor; weight loss; subcutaneous; oral